61 results about "Inflammatory infiltration" patented technology

The invention discloses a nano-enzyme microneedle system for remodeling a diabetes wound microenvironment to promote healing and a preparation method of the nano-enzyme microneedle system. The nano-enzyme microneedle system comprises nano-enzyme and a microneedle carrier, the nano-enzyme is prepared by a self-assembly method and is loaded in the microneedle carrier; the microneedle carrier is composed of a hydrogel matrix and is molded into a microneedle array through 3D printing; according to the system, the nano-enzyme can be delivered to the corium layer by penetrating the cuticle of the skin through the microneedle. The traditional Chinese medicine composition has the advantages that ROS (reactive oxygen species) is efficiently removed, oxidative stress injury induced by high glucose (HG) is relieved, immune cell polarization is regulated, inflammatory factor release is regulated and controlled, the chronic inflammation state of wound surfaces is relieved, cell proliferation and migration are promoted, neovascularization is accelerated, the healing speed of the diabetic wound surfaces is obviously increased, inflammation infiltration is reduced, granulation tissue formation and collagen deposition are obviously improved, and the effect of treating diabetes mellitus is achieved. And no systemic toxicity is observed. Through the synergistic effect of resisting oxidation, resisting inflammation and promoting angiogenesis, the pathological microenvironment of the diabetic wound is effectively improved.

The invention discloses a biological medicine application of luwulinine, and provides and verifies that luwulinine can inhibit disulfiram death of cells for the first time, so that luwulinine can be used for preventing or treating hepatic ischemia reperfusion injury. Experimental data show that the luteiniine can relieve liver function injury after reperfusion with cell apoptosis, tissue inflammation infiltration and tissue fibrosis as manifestations, and a new direction is provided for mechanism research and prevention and treatment of hepatic ischemia reperfusion injury.

The application discloses an active polypeptide and application thereof in treating diabetic peripheral neuropathy, and belongs to the technical field of biological polypeptide drugs. An amino acid sequence of the active polypeptide is QVWPDGFVGLAKLWI, which is obtained by step-by-step enzymatic extraction and purification from Morus alba L. which is a homology of medicine and food. The polypeptide can significantly inhibit oxidative stress, inflammatory infiltration and cell apoptosis of Schwann cells induced by a high-sugar environment, and repair the function of damaged nerve cells. Meanwhile, the polypeptide can effectively improve abnormal sciatic nerve conduction function of a diabetic model mouse. The active polypeptide can be used for preparing a drug for treating diabetic peripheral neuropathy, and provides a new candidate drug and research and development direction for the targeted treatment of diabetic peripheral neuropathy.

The invention provides an application of a Ly6G antibody in treatment of pneumonia caused by novel coronavirus, and the Ly6G antibody can effectively reduce the lung inflammatory infiltration degree after novel coronavirus infection, reduce the expression level of cytokines, chemotactic factors or NETs related proteins, and inhibit formation of NETs. The invention provides a brand new treatment strategy for novel coronavirus infection, especially severe pneumonia caused by multiple infection of novel coronavirus.

The invention discloses application of cynarin in preparation of a medicine for resisting respiratory syncytial virus. The cynarin is polyphenolic acid cynarin, and the respiratory syncytial virus is an RSV-A2 strain; the compound can effectively inhibit replication of respiratory syncytial viruses, is a monomer component of natural medicinal plants, is clear in structure, stable in chemical property, easy in quality control and free of obvious toxic and side effects, can effectively resist inflammation while serving as an active component of a natural small-molecule antiviral drug, and has a broad application prospect. Viral lung inflammatory infiltration and lung injury caused by the respiratory syncytial virus are relieved.

The invention discloses a cascade targeted drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention designs a drug delivery system with a cascade targeting function, and the drug delivery system is used for delivering a phosphodiesterase 4 inhibitor A5. Through polypeptide modification and exosome fusion, phagocytosis and ingestion of cells to a drug delivery system are promoted, and the bioavailability of the drug is significantly improved. The drug delivery system shows excellent in-vivo lung targeting, can effectively inhibit the aggravation of inflammatory infiltration in the lung, and plays a role in treating acute lung injury. The invention provides a new strategy for improving the targeting property and the utilization rate of the medicine, provides a new medicine for treating the acute lung injury, and has a wide application prospect and an extremely high application value.

Disclosed are a myocarditis-targeted radionuclide molecular probe, a preparation method therefor, and an application thereof. The myocarditis-targeted radionuclide molecular probe includes a DPP4 inhibitor, a bifunctional chelator covalently bonded to an amino group of the DPP4 inhibitor, and a metallic radionuclide coordinately bonded to the bifunctional chelator. The myocarditis-targeted radionuclide molecular probe provided by the present disclosure exhibits high specificity and good targeting capability, and demonstrates significant uptake in myocardial inflammatory cells, and low uptake in non-target tissues. Characterized by high resolution and sensitivity of imaging, the myocarditis-targeted radionuclide molecular probe is applied for early diagnosis of cardiac inflammatory infiltration severity, therapeutic efficacy evaluation, prognosis assessment and the like, and has promising clinical and application prospects in the field of non-invasive nuclear medicine diagnosis and treatment as a myocarditis imaging agent.

The present invention provides use of lifitegrast in the preparation of a drug for treating retinal artery occlusion injury. Lifitegrast can effectively reduce retinal artery occlusion injury and apoptosis of retinal ganglion cells and has the effect of inhibiting inflammatory infiltration in the retina and activation of microglia. Moreover, lifitegrast has the effect of reducing retinal ganglion cell injury. Lifitegrast can be used for related diseases such as neuroinflammatory injury caused by retinal artery occlusion.

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

The invention relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases), and particularly relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases). The invention relates to an application of MASLD in a medicine, and belongs to the technical field of biological medicines. In an in-vivo experiment, a mouse MASLD model is established by adopting methionine choline deficiency diet induction, and the treatment effect of cepharanthine on MASLD is researched. Experimental results show that the cepharanthine can significantly reduce the levels of triglyceride, glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and other indexes of MASLD mice; a pathological detection result shows that cepharanthine can effectively reduce liver lipid deposition and inflammatory infiltration. In-vitro experiments prove that cepharanthine can effectively reduce the content of free fatty acid (Free Fatty Acid); fFA (Fatty Acid) induced HepG2 (HepG2) cell lipid accumulation and lipopolysaccharides (lipopolysaccharides) induced HepG2 cell lipid accumulation and lipopolysaccharides (FFA) induced HepG2 cell lipid accumulation; the THP-1 cell inflammatory response is induced by LPS (Lipopolysaccharide). In conclusion, the cepharanthine shows remarkable anti-lipid accumulation and anti-inflammatory effects in in-vivo and in-vitro experiments, can be used for preparing the medicine for preventing or treating MASLD, and has a wide application prospect.

The invention discloses a supramolecular compound and a preparation method and application thereof.The supramolecular compound is carrier-free nanoparticles (CDN) obtained by conducting molecular self-assembly on tripterine (CeL) and demethylwedelolactone, and experiments show that the CDN can effectively relieve clinical symptoms, inflammation infiltration and bone erosion. Besides, the CDN can be transferred to an inflammation part of rheumatoid arthritis (RA) in a targeted manner, so that bone degenerative change and joint skeleton damage can be remarkably reduced, the inflammation part is targeted, the expression of proinflammatory cytokines is reduced, the drug concentration of the affected part is improved, and the toxic and side effects of the tripterine are reduced. The research provides a new strategy for improving the curative effect and safety of the traditional Chinese medicine, and provides a brand new solution for RA treatment.

The invention relates to application of hispidulin or pharmaceutically acceptable salts, esters and solvates thereof in preparation of medicines for treating lupus nephritis. The invention develops a new application of the hispidulin, and proves the treatment effect of the hispidulin on lupus nephritis. Meanwhile, the invention verifies that the hispidulin can obviously improve the renal function indexes (including reducing urine protein, blood urea nitrogen and serum creatinine, increasing serum albumin and improving lipid metabolism) of lupus nephritis, can relieve renal pathological injuries (including reducing glomerular mesangial hyperplasia, basilar membrane thickening, renal tubule dilatation and interstitial inflammation infiltration), and can improve the renal function indexes of lupus nephritis. Kidney immune complex deposition can be reduced (including reduction of deposition of kidney IgG and complement C3), meanwhile, it is found for the first time that angiogenin-like protein 4 (Angptl4) is a key action target for treating lupus nephritis by means of the homospidulin, and the homospidulin plays a kidney protection role by down-regulating Angptl4 expression.

The application relates to the technical field of aquatic virus prevention and treatment, and particularly discloses application of YTX in preparation of a medicine for preventing and treating SCRV infection. The application verifies the prevention and treatment effects of YTX on SCRV infection through fish body level experiments. The experimental results show that, in a safe concentration range, YTX can significantly improve the survival rate of fish after SCRV infection by being administered through soaking or injection, the relative protection rate is more than 85%; the virus load in target organs such as kidneys and spleens is significantly reduced, the virus copy number is reduced by 2-3 logarithmic levels; and the pathological damage such as tissue necrosis and inflammatory infiltration caused by the virus is effectively reduced. The application verifies the anti-SCRV effect of YTX at the fish body level for the first time, provides key data support for development and application of YTX as a new aquatic antiviral preparation, and has important industrial application value.

A cannabidiol composite reagent for resisting muscle aging belongs to the technical field of biomedicine, and is characterized in that 0.6 g of cannabidiol is firstly weighed and dissolved in 4 mL of edible linoleic acid, and the cannabidiol composite reagent is prepared by uniformly mixing on a vortex oscillator; research finds that the cannabidiol composite reagent can reduce muscle fiber fracture, inflammation infiltration and cell deformation and swelling during aging and increase the muscle fiber area, and experiments prove that the cannabidiol composite reagent can resist oxidative damage in the muscle aging process and relieve muscle tissue aging.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating bacterial liver injury of chicks. The traditional Chinese medicine composition is prepared from herba artemisiae scopariae and radix scutellariae. For bacterial infection and immunological liver injury triggered by endotoxin, through compatibility and synergy of'one clearing and one benefiting 'of two medicines, pathogen stimulation and immune overresponse links are intervened at the same time, and growth inhibition caused by liver injury is blocked. The traditional Chinese medicine composition is extracted and prepared into oral liquid, powder and other dosage forms, and then is applied to chicks at the age of 6-12 days. Experiments prove that the traditional Chinese medicine composition can significantly reduce the activity of liver injury markers such as serum ALT and AST, alleviate liver inflammatory infiltration and necrosis, can reverse the decrease of average daily gain caused by liver injury, synchronously realizes liver injury repair and growth performance guarantee, adapts to resistance reduction / forbidden resistance trends, and has a broad application prospect. And a safe and effective solution is provided for preventing and treating bacterial liver injury in the early brooding stage of broilers.

The invention discloses a fusion protein CTB-3MOG34-56, a DNA (deoxyribonucleic acid) molecule, a recombinant vector and application of the fusion protein CTB-3MOG34-56. Belongs to the technical field of biological medicine. The CTB-3MOG34-56 fusion protein is constructed for the first time, and it is proved that the CTB-3MOG34-56 fusion protein can significantly inhibit disease progression of EAE mice through oral administration or nasal mucosa administration, reduce inflammatory infiltration of a central nervous system and significantly inhibit Th17-mediated inflammation (IL-17A and IL-6) and TNF-alpha pathways at the same time; and the TGF-beta is specifically up-regulated to enhance the immunosuppression function of Treg. The fusion protein has the effects of prophylactic immunoregulation and therapeutic neuroprotection, provides a new potential candidate drug for the treatment of experimental autoimmune encephalomyelitis and multiple sclerosis, and has a wide clinical application prospect.

The application relates to a compound traditional Chinese medicine composition for treating dermatitis of tumor patients, which is prepared from the following raw materials in parts by weight: 20-40 parts by weight of Huangqi, 5-15 parts by weight of Wumei, 5-15 parts by weight of Baishao, 5-15 parts by weight of Dilong and 10-20 parts by weight of Danshen, and a preparation method thereof is disclosed. The application can obviously improve the clinical dermatitis score related to skin lesions, reduce the spleen coefficient index, and also has the functions of reducing the epidermal thickness and inflammatory infiltration such as mast cells in the dermis, and reducing the inflammatory factor level in the skin lesions, which shows that the application can treat dermatitis of tumor patients.

The application discloses application of a benzofuro[3,2-c]quinolinone compound in preventing and treating metabolic dysfunction related steatohepatitis. The compound P82, i.e. 3,8-dihydroxybenzofuro[3,2-c]quinolin-6(5H)-one, is prepared through synthesis and purification of an intermediate, and can obviously improve liver steatosis, inflammatory infiltration and fibrosis in a metabolic dysfunction related steatohepatitis model induced by HFHC, thereby effectively delaying the progress of metabolic dysfunction related steatohepatitis. Meanwhile, the compound can improve lipid accumulation of liver cells induced by oleic acid and palmitic acid, and is expected to be developed into a new drug for preventing and treating metabolic dysfunction related steatohepatitis.

The invention discloses a new application of benzbromarone or pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. The invention belongs to the technical field of medicine. Experimental results show that the benzbromarone can significantly reduce collagen deposition and inflammatory infiltration in lung tissues, reduce fibrosis area, improve lung functions of patients with pulmonary fibrosis, inhibit lung fibroblast activation and inhibit fibrosis progress. The action mechanism of the gene is related to inhibition of expression of BAG2, FN1, Collagen I and protein. The invention provides a brand new medicine choice for treating pulmonary fibrosis, has the unique advantage of new use of old medicine, and has the potential of short research and development period, known safety and definite curative effect. Meanwhile, the invention further expands the application of benzbromarone in preparation of the protein inhibitor and the in-vitro reagent.

The application of mussel polysaccharide in preparation of a medicine for regulating the intestine-liver axis to treat alcoholic liver injury belongs to the technical field of natural products and biological medicine. The method takes mussel polysaccharide as an active ingredient, and divides experimental mice into a normal control group, an alcoholic liver injury model group, a positive control group and mussel polysaccharide low-, medium- and high-dose groups (60, 120 and 180 mg / kg / day), and continuously intervenes for 4 weeks. The results show that the mussel polysaccharide can significantly reduce liver function indexes such as ALT and AST, improve TC, TG, LDL-C, HDL-C related blood lipid disorders, protect the colon mucosal barrier, regulate the intestine-liver axis homeostasis, effectively reduce alcohol-induced liver fatty degeneration, inflammatory infiltration and oxidative stress injury, and the effect shows obvious dose dependence. The mussel polysaccharide is safe, non-toxic, economical in source, simple in intervention method and strong in repeatability, and provides a new way for the development of functional food and liver protection products for preventing and treating alcoholic liver injury.

The invention discloses application of a Reg4 gene in treatment of metabolism-related fatty liver, and relates to the technical field of biomedicine. The Reg4 gene is applied to the aspect of treating obesity and metabolism-related fatty liver; according to the application, by increasing expression of the Reg4 gene, liver lipid deposition, liver cell ballooning and inflammatory infiltration related to the metabolism-related fatty liver are inhibited; the application is realized by inhibiting the processes of de novo synthesis of fat in the liver, liver lipid uptake and fatty acid beta oxidation. The step of inhibiting the de novo synthesis of fat in the liver comprises the step of inhibiting the expression of genes of acetyl coenzyme A carboxylase 1, fatty acid synthase and / or stearoyl coenzyme A desaturase 1. The invention definitely proves that the Reg4 gene has an obvious effect of improving obesity and metabolism-related fatty liver, and can relieve hepatic fatty degeneration and inflammation.

The invention discloses a rat parotitis model construction method based on general anesthesia and parotid gland directional injection, which belongs to the technical field of biology and comprises the steps of animal preparation, anesthesia, disinfection incision exposure, LPS injection and postoperative care. The method has the advantages that the parotid gland is directly exposed by adopting a longitudinal incision of the cheek, 2mg / mL LPS (0.2 mL and depth of 2mm) is injected, microscope positioning is not needed, the operation is simple and convenient, inflammation is limited to the parotid gland, pathological characteristics (alveolar injury, inflammatory infiltration and saliva reduction) are consistent with those of clinical application, the success rate is greater than or equal to 90%, and compared with an existing catheter injection method, the method is high in repeatability, less in interference and suitable for disease mechanism research and drug screening.

This invention belongs to the field of biomedical technology, specifically disclosing the application of cimicifuga in the preparation of drugs for treating periodontitis. Specifically, it relates to the application of cimicifuga in the preparation of drugs for treating periodontitis; and the application of cimicifuga in the preparation of drugs for treating alveolar bone defects (periodontal bone defects) caused by periodontitis. It also relates to the application of cimicifuga in the preparation of products for inhibiting macrophage polarization towards M1 and / or promoting macrophage polarization towards M2 in a single macrophage system. In this disclosure, cimicifuga has no significant toxicity to macrophages and has high safety; it targets and regulates macrophage polarization, inhibiting periodontal inflammation at its source; it significantly reduces inflammatory infiltration and osteoclast formation in periodontal tissues, effectively alleviating alveolar bone defects; and it provides a novel targeted immunotherapy drug for periodontitis, expanding the clinical application of single traditional Chinese medicine monomers.

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

The invention discloses an application of a gene for coding LRP1-beta chain oligopeptide as a target in screening / preparing a medicine for treating aortic dissection, an application of a reagent for inducing overexpression of the LRP1-beta chain oligopeptide in preparing the medicine for treating the aortic dissection, and an application of the LRP1-beta chain oligopeptide as a biomarker in preparing an aortic dissection diagnostic reagent. Experiments prove for the first time that the LRP1-beta chain oligopeptide can inhibit phenotypic transformation of vascular smooth muscle cells and inflammatory infiltration of macrophages by down-regulating expression of OPN, alleviate inflammatory response and relieve or inhibit occurrence and development of aortic dissection, provides a new direction and thought for treatment of aortic dissection, and has broad application prospects in treatment of aortic dissection. The compound is expected to be applied to research and development of new drugs for treating aortic dissection

The invention relates to application of a qi-regulating and blood-activating preparation in a medicine for preventing or treating altitude stress, and belongs to the technical field of medicine application. The qi-regulating and blood-activating preparation is prepared by extracting and processing fructus cinnamoii, borneol, ligusticum wallichii and allium macrostemon. Experimental research shows that the qi-regulating and blood-activating preparation can effectively improve plateau hypoxia athletic ability and heart functions, can effectively improve plateau hypoxia lung tissue inflammation infiltration, reduces alveolar wall thickness, reduces lung tissue fibrosis, and reduces myocardial cell LDH release, thereby achieving the effect of effectively preventing and treating acute altitude stress.

This invention provides a topical traditional Chinese medicine preparation for treating fungal skin infections and its preparation method, belonging to the field of biomedical technology. The topical traditional Chinese medicine preparation is based on traditional Chinese medicine theory and scientifically formulated, using *Ling Shou Ci*, *Da Cha Gen*, *Fu Fang Teng*, *Mesona chinensis*, *Bai La Jiao*, *Bai Niu Wei Qi*, *Nai Zhi Shu*, *Di Yu*, and *Er Cao* as raw materials. The extracts prepared from the above-mentioned medicinal materials exhibit strong antibacterial and bactericidal effects against *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Microsporum gypseum*, inhibiting the development of pathogens at the source. The topical traditional Chinese medicine preparation can significantly inhibit the body's inflammatory response, effectively improving and alleviating skin lesions such as erythema, papules, desquamation, alopecia, and inflammatory infiltration caused by fungal infections. It has a significant therapeutic effect on fungal skin diseases, and the topical traditional Chinese medicine preparation provided by this invention has great potential for application in the treatment of fungal skin diseases.

The invention belongs to the field of medicine application, and particularly relates to application of polygonum multiflorum and an extract thereof in preparation of a medicine for repairing diabetic wounds. Cell experiments show that the polygonum multiflorum ethanol extract has remarkable in-vitro antioxidant activity and good cell safety, and can effectively enhance proliferation, migration, apoptosis resistance and oxidative stress resistance of human umbilical vein endothelial cells in a high-glucose environment by activating a P62-Keap1-Nrf2 signal channel. Animal experiments further prove that the extracting solution can remarkably accelerate wound healing of diabetic mice, relieve local inflammation infiltration, increase the collagen content, promote transformation of the diabetic mice to mature collagen and reduce the oxidative stress level of tissues at the same time. The treatment effect of the radix polygoni multiflori is equivalent to that of a clinical common drug basic fibroblast growth factor, and the radix polygoni multiflori has a wide application prospect in the aspect of wound repair of diabetes mellitus.

The invention relates to a preparation method and application of 1-hydroxypalmatine, and belongs to the technical field of biology. According to the method, the ethanol solution is adopted for extracting the corydalis pallida, after a solvent is removed, silica gel column chromatography and MCI column chromatography are sequentially carried out, then semi-preparative liquid chromatography purification and LH-20 gel column chromatography are adopted, the high-purity 1-hydroxypalmatine is obtained, the purity is 96% or above, the preparation process is simple, and the cost is low. The prepared 1-hydroxypalmatine is used for treating ulcerative colitis, and can inhibit weight loss of individuals with ulcerative colitis, reduce DAI score, prolong colon length, relieve inflammation infiltration degree, repair inflammation and intestinal barrier injury in colon tissues and effectively treat ulcerative colitis.